cに応じられた阻害 | c-Met Inhibition
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
CRZ in MET-Rearranged NSCLC - Lung Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
![Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]](https://www.ijbs.com/v16/p2595/toc.jpg "Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]")
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. - Abstract - Europe PMC
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram
Crizotinib (PF-02341066) | ALK/c-Met/ROS1阻害剤 | MedChemExpress
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
MET mutations identified following crizotinib treatment. (A–C) The... | Download Scientific Diagram
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer
